Page 7 - Explorer Array News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investegate announcements from Oxford BioDynamics, PDMR Dealing

Investegate announcements from Oxford BioDynamics, PDMR Dealing

About Oxford BioDynamics Plc Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications. In March 2021, the Company launched its first commercial prognostic...

    Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, announces that it has today granted a total of 1,632,798 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to certain Group employees, including 462,798 options to Chief Executive Officer, Dr Jon Burrows, 480,000 options to Chief Financial Officer, Paul Stockdale and 150,000 options to Chief Operating Officer, Thomas Guiel, who is a person discharging manageria...

at Oxford Business Park, supporting expanded strategy Oxford, UK - 9 April 2021 -  Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D genomics platform, has signed a lease agreement for new laboratory and office space at Oxford Business Park , to significantly expand its UK facilities. The 24,000 sq ft premises will house the Company's growing UK infrastructure, as it continues the execution of its expanded strategic focus , announ...